首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   21791篇
  免费   2436篇
  国内免费   69篇
耳鼻咽喉   159篇
儿科学   731篇
妇产科学   814篇
基础医学   3033篇
口腔科学   556篇
临床医学   2586篇
内科学   4789篇
皮肤病学   306篇
神经病学   1672篇
特种医学   868篇
外科学   2614篇
综合类   482篇
一般理论   35篇
预防医学   2280篇
眼科学   342篇
药学   1985篇
中国医学   11篇
肿瘤学   1033篇
  2021年   287篇
  2020年   187篇
  2019年   327篇
  2018年   359篇
  2017年   282篇
  2016年   292篇
  2015年   322篇
  2014年   479篇
  2013年   629篇
  2012年   947篇
  2011年   976篇
  2010年   511篇
  2009年   483篇
  2008年   846篇
  2007年   1015篇
  2006年   914篇
  2005年   901篇
  2004年   893篇
  2003年   826篇
  2002年   808篇
  2001年   742篇
  2000年   814篇
  1999年   677篇
  1998年   279篇
  1997年   239篇
  1996年   233篇
  1995年   256篇
  1994年   233篇
  1993年   212篇
  1992年   525篇
  1991年   544篇
  1990年   525篇
  1989年   527篇
  1988年   485篇
  1987年   496篇
  1986年   449篇
  1985年   419篇
  1984年   365篇
  1983年   292篇
  1982年   233篇
  1981年   193篇
  1980年   174篇
  1979年   286篇
  1978年   280篇
  1977年   198篇
  1976年   205篇
  1975年   194篇
  1974年   209篇
  1973年   175篇
  1972年   201篇
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
3.
4.
In May 2017, the Health and Environmental Sciences Institute's Genetic Toxicology Technical Committee hosted a workshop to discuss whether mode of action (MOA) investigation is enhanced through the application of the adverse outcome pathway (AOP) framework. As AOPs are a relatively new approach in genetic toxicology, this report describes how AOPs could be harnessed to advance MOA analysis of genotoxicity pathways using five example case studies. Each of these genetic toxicology AOPs proposed for further development includes the relevant molecular initiating events, key events, and adverse outcomes (AOs), identification and/or further development of the appropriate assays to link an agent to these events, and discussion regarding the biological plausibility of the proposed AOP. A key difference between these proposed genetic toxicology AOPs versus traditional AOPs is that the AO is a genetic toxicology endpoint of potential significance in risk characterization, in contrast to an adverse state of an organism or a population. The first two detailed case studies describe provisional AOPs for aurora kinase inhibition and tubulin binding, leading to the common AO of aneuploidy. The remaining three case studies highlight provisional AOPs that lead to chromosome breakage or mutation via indirect DNA interaction (inhibition of topoisomerase II, production of cellular reactive oxygen species, and inhibition of DNA synthesis). These case studies serve as starting points for genotoxicity AOPs that could ultimately be published and utilized by the broader toxicology community and illustrate the practical considerations and evidence required to formalize such AOPs so that they may be applied to genetic toxicity evaluation schemes. Environ. Mol. Mutagen. 61:114–134, 2020. © 2019 Wiley Periodicals, Inc.  相似文献   
5.
6.
7.
8.
Partial nephrectomy is the mainstay of treatment for localized kidney cancer. A proportion of patients are upstaged post-operatively to locally advanced di  相似文献   
9.
Tranexamic acid (TXA) is an antifibrinolytic drug that reduces surgical blood loss and death due to bleeding after trauma and post‐partum haemorrhage. One key issue for treatment success is early administration. While usually given intravenously, oral and intramuscular use would be useful in specific circumstances. Therefore, an understanding of TXA pharmacokinetics when given via different routes is valuable. The aim of this study was to perform an individual participant data meta‐analysis of pharmacokinetic studies with TXA given to healthy volunteers via different routes. We searched the following databases: PubMed, Web of Science, Wiley Online Library, Elsevier Science Direct and J‐STAGE. Individual subject data were extracted when available, otherwise arithmetic means were used. A population pharmacokinetic model was developed using nonlinear mixed effect modelling. Seven studies were included in the analysis with data from 10 patients for the IV route, six patients for the IM route and 114 patients for the oral route. The pharmacokinetics was ascribed to a two‐compartment model, and the main covariate was allometrically scaled bodyweight. Oral and IM bioavailabilities were 46 and 105%, respectively. For a 70 kg bodyweight, the population estimates were 7.6 L/h for clearance, 17.9 L for the volume of the central compartment, 2.5 L/h for the diffusional clearance and 16.6 L for the peripheral volume of distribution. Larger well‐designed studies are needed to describe the pharmacokinetics of TXA when given IM or as an oral solution before these can be recommended as alternatives to IV.  相似文献   
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号